Glucosum Et Natrium Chloratum 2:1 Fresenius

Glucosum Et Natrium Chloratum 2:1 Fresenius is an intravenous solution containing sodium chloride and glucose monohydrate in a 2:1 ratio. It is supplied as a sterile liquid for infusion, intended for fluid and electrolyte replacement in clinical settings. The product is manufactured in the European Union and requires a prescription. It is packaged in infusion bags and used under medical supervision to restore fluid volume and provide an energy substrate.

Glucosum Et Natrium Chloratum 2:1 is indicated for clinical situations where rapid fluid and electrolyte replacement is required.

- Rehydration of patients with dehydration due to vomiting, diarrhea, or excessive sweating. - Replacement of sodium and chloride losses in surgical or trauma patients. - Support of blood glucose levels in individuals at risk of hypoglycemia. - Maintenance of fluid balance during peri‑operative care or intensive‑care monitoring. - Adjunct therapy for electrolyte correction in metabolic disorders such as hyponatremia.

The safety profile of the solution reflects the components of sodium chloride and glucose, with most reactions being mild and related to the infusion process.

Common: - Mild local irritation or erythema at the infusion site. - Transient increase in blood glucose concentration. - Slight electrolyte shifts causing mild nausea. - Low‑grade headache or dizziness during rapid infusion.

Serious: - Hypernatremia leading to neurological symptoms. - Severe hyperglycemia, especially in diabetic patients. - Fluid overload with pulmonary edema.

Clinicians should evaluate patient-specific factors before administering Glucosum Et Natrium Chloratum 2:1 to minimize risks.

- Assess baseline serum electrolytes and glucose before infusion. - Adjust infusion rate in patients with cardiac or renal impairment. - Avoid use in individuals with known hypersensitivity to sodium chloride or glucose solutions. - Monitor fluid balance and weight to prevent overload. - Use caution in pregnant or lactating women; limited safety data are available. - Do not mix with incompatible medications or solutions without compatibility testing.

The solution may interact with other intravenous agents or affect the pharmacokinetics of certain drugs.

Avoid: - Co‑administration with hypertonic saline solutions, which can cause excessive sodium load. - Simultaneous infusion of potassium‑containing preparations without electrolyte monitoring.

Use with caution: - Concurrent use of insulin or oral hypoglycemics; monitor blood glucose closely. - Administration with nephrotoxic drugs; watch for altered renal handling of electrolytes. - Use alongside diuretics; electrolyte shifts may be amplified.